Philip M Murphy Selected Research

plerixafor

10/2019	Plerixafor for the Treatment of WHIM Syndrome.
1/2019	Plerixafor for the Treatment of WHIM Syndrome. Reply.
12/2018	Metagenomic Discovery of 83 New Human Papillomavirus Types in Patients with Immunodeficiency.
1/2017	Pathogenesis, diagnosis and therapeutic strategies in WHIM syndrome immunodeficiency.
6/2015	CXCR4 antagonist AMD3100 redistributes leukocytes from primary immune organs to secondary immune organs, lung, and blood in mice.
4/2014	A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.
1/2014	International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.
11/2011	The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.
10/2011	AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome.
10/2010	Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philip M Murphy Research Topics

Disease

18	WHIM syndrome 01/2021 - 10/2010
18	Inflammation (Inflammations) 01/2021 - 03/2002
17	Infections 01/2021 - 11/2002
14	Atherosclerosis 06/2015 - 02/2003
9	Neoplasms (Cancer) 01/2021 - 11/2002
8	Neutropenia 10/2019 - 10/2003
5	Fibrosis (Cirrhosis) 01/2019 - 02/2004
5	Atherosclerotic Plaque (Atheroma) 06/2015 - 08/2006
5	West Nile Fever 03/2011 - 10/2005
4	Warts (Wart) 01/2021 - 01/2007
4	Primary Immunodeficiency Diseases 10/2019 - 01/2017
3	Agammaglobulinemia (Hypogammaglobulinemia) 01/2021 - 01/2007
3	Bacterial Infections (Bacterial Infection) 01/2020 - 11/2002
3	Cardiovascular Diseases (Cardiovascular Disease) 06/2012 - 04/2003
3	Reperfusion Injury 12/2008 - 08/2006
3	Wounds and Injuries (Trauma) 07/2008 - 03/2004
2	Communicable Diseases (Infectious Diseases) 01/2020 - 12/2003
2	Cytopenia 10/2019 - 04/2014
2	Chromothripsis 01/2018 - 02/2015
2	Alzheimer Disease (Alzheimer's Disease) 01/2015 - 11/2002
2	Acquired Immunodeficiency Syndrome (AIDS) 01/2014 - 07/2006
2	Pneumonia (Pneumonitis) 01/2011 - 11/2003
2	Disease Progression 01/2010 - 02/2003
2	Glycogen Storage Disease IB 09/2006 - 10/2003
2	Glycogen Storage Disease (Glycogenosis) 09/2006 - 10/2003
1	Candidiasis (Moniliasis) 09/2021
1	Blister (Bulla) 01/2021
1	Cataract (Cataracts) 01/2021
1	Colitis 01/2021
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 01/2021
1	Eye Infections 01/2021
1	Lymphopenia (Lymphocytopenia) 01/2021
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2021
1	Mycoses (Diseases, Fungus) 01/2021
1	Papillorenal syndrome 01/2021
1	Rupture 01/2021
1	Coronavirus Infections 01/2020
1	Toxoplasmosis 01/2019
1	Vasculitis (Vasculitides) 01/2019
1	Protozoan Infections 01/2019
1	Myositis (Idiopathic Inflammatory Myopathies) 01/2019
1	Blindness (Hysterical Blindness) 01/2019
1	Papilloma (Papillomatosis) 12/2018
1	Epidermodysplasia Verruciformis 12/2018
1	Leukopenia 01/2018
1	Persistent Infection 01/2017

Drug/Important Bio-Agent (IBA)

37	Chemokine ReceptorsIBA 01/2021 - 01/2002
32	ChemokinesIBA 01/2021 - 03/2002
14	LigandsIBA 01/2019 - 11/2002
10	plerixafor FDA Link 10/2019 - 10/2010
5	Apolipoproteins E (ApoE)IBA 06/2015 - 02/2003
5	Chemokine CX3CL1IBA 01/2015 - 08/2004
5	Chemotactic FactorsIBA 01/2011 - 11/2002
4	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 10/2019 - 10/2003
4	Pharmaceutical PreparationsIBA 12/2018 - 02/2004
4	CytokinesIBA 06/2015 - 07/2007
4	CalciumIBA 07/2012 - 10/2003
3	GTP-Binding Proteins (G-Protein)IBA 01/2021 - 04/2014
3	Formyl Peptide Receptors (Formyl Peptide Receptor)IBA 01/2021 - 11/2002
3	Proteins (Proteins, Gene)FDA Link 01/2020 - 10/2003
3	Antiviral Agents (Antivirals)IBA 01/2020 - 12/2003
3	ApolipoproteinsIBA 06/2015 - 08/2011
3	LipidsIBA 02/2013 - 08/2006
3	Glucose (Dextrose)FDA LinkGeneric 10/2010 - 10/2003
2	VaccinesIBA 01/2021 - 04/2014
2	AntibodiesIBA 01/2021 - 09/2015
2	Dextran SulfateIBA 01/2021 - 04/2013
2	InterferonsIBA 01/2021 - 02/2003
2	CXCR4 Receptors (CXCR4 Receptor)IBA 10/2019 - 01/2018
2	CC ChemokinesIBA 01/2017 - 12/2004
2	Interleukin-10 (Interleukin 10)IBA 01/2012 - 06/2006
2	Glucose-6-PhosphateIBA 10/2010 - 10/2003
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 06/2009 - 11/2002
2	Messenger RNA (mRNA)IBA 07/2008 - 09/2004
2	Chemokine CCL5IBA 06/2006 - 02/2003
2	BX 471IBA 04/2005 - 02/2004
1	AutoantibodiesIBA 09/2021
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	Sirolimus (Rapamycin)FDA Link 01/2021
1	STAT1 Transcription FactorIBA 01/2021
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2021
1	MitogensIBA 01/2021
1	Janus KinasesIBA 01/2021
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Sulfadiazine (Sulphadiazine)FDA Link 01/2019
1	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric 01/2019
1	benzonidazole (benznidazole)IBA 01/2019
1	Retinaldehyde (Retinal)IBA 01/2019
1	Pyrimethamine (Daraprim)FDA Link 01/2019
1	ArrestinIBA 01/2019
1	Circular DNAIBA 12/2018
1	Immunoglobulin G (IgG)IBA 04/2016

Therapy/Procedure

7	Therapeutics 12/2018 - 02/2003
5	Transplantation 01/2018 - 03/2002
2	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2018 - 01/2015
2	Hematopoietic Stem Cell Mobilization 04/2014 - 01/2014
2	Immunotherapy 08/2004 - 11/2002
1	Precision Medicine 01/2019
1	Splenectomy 01/2018